BS_FCAKKZ20
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 49.5400788436268
- age_years
- 15.162
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.538
- G2M_CHECKPOINT+0.521
- MYC_TARGETS_V1+0.460
- MYC_TARGETS_V2+0.420
- PANCREAS_BETA_CELLS+0.338
- MITOTIC_SPINDLE+0.293
- SPERMATOGENESIS+0.132
- DNA_REPAIR+0.127
- HEDGEHOG_SIGNALING+0.053
- KRAS_SIGNALING_DN-0.008
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.527
- INTERFERON_ALPHA_RESPONSE-0.517
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.497
- INTERFERON_GAMMA_RESPONSE-0.496
- TNFA_SIGNALING_VIA_NFKB-0.479
- INFLAMMATORY_RESPONSE-0.467
- TGF_BETA_SIGNALING-0.462
- ANGIOGENESIS-0.458
- NOTCH_SIGNALING-0.419
- IL2_STAT5_SIGNALING-0.376
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_AM70R8RG | medulloblastoma | — | 0.975 |
| 2 | BS_3F5PR9GS | medulloblastoma | — | 0.972 |
| 3 | BS_W644VEVE | medulloblastoma | — | 0.966 |
| 4 | BS_EFE4YEK3 | medulloblastoma | — | 0.963 |
| 5 | BS_TYAYZ9ZW | medulloblastoma | — | 0.962 |
| 6 | BS_45J79YTF | high-grade glioma | — | 0.960 |
| 7 | BS_7XQRH69M | medulloblastoma | — | 0.959 |
| 8 | BS_QHS3V0GP | Embryonal tumors | — | 0.958 |
| 9 | BS_9NZ2D6AD | medulloblastoma | — | 0.957 |
| 10 | BS_5VQP0E6K | medulloblastoma | — | 0.956 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.538 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.521 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.338 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.132 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.127 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.053 | Inavolisib | — uncovered |